N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Not applicable ClinicalTrials.gov

Interventional Study on Smoking Reduction in Psychiatry

Sponsor: GCS-CCOMS • ClinicalTrials.gov ID: NCT06926153

Registry updated: 2026-10-08
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

The smoking rate among people with mental disorders is higher than in the general population. Greater exposure to the harmful effects of tobacco partly explains the major inequality in life expectancy observed among people with mental disorders who, depending on the disorder and the study, live 10 to 25 years less than the general population, a gap mainly due to the occurrence of cardiovascular and respiratory pathologies, notably bronchial cancers. However, tobacco reduction actions specifically targeting these people remain insufficiently developed, particularly in psychiatry where this addiction is often banalized and its treatment neglected. The objective of this study is to evaluate an intervention ('Tabapsy') co-constructed with mental health services users, mental health professionals, and general practitioners and targeting adult patients followed in ambulatory psychiatry. The main objective is to evaluate the effectiveness of the intervention on short-term smoking cessation (cessation for at least 7 days) among regular smokers at 3 months. Secondary objectives include evaluation of its cost-effectiveness and implementation. To this end, a national cluster-randomized controlled study will be carried out, supplemented by qualitative interviews to study the implementation of the intervention.

Interventions

  • TABAPSY (Other)
    The Tabapsy intervention consists in a campaign to promote smoking cessation within the CMP, and an intervention to help people stop smoking which comprises of a) A general information meeting; b) An assessment workshop, to evaluate level of dependence using validated tests and establish a personalized cessation program based on the results obtained; c) Five thematic workshops to support cessation, covering 1/ nicotine replacement treatments, electronic cigarettes and other drug treatments available for smoking cessation, 2/ emotional management, 3/ weight gain, 4/ physical activities, and 5/ manual occupations; d) Peer support groups, based on the sharing of experiences, to encourage mutual aid and solidarity between people with mental disorders who are trying to quit smoking. The intervention relies on a facilitator specifically recruited to implement and run the intervention in the CMP. It is complemented by a website that will contain all the resources and information presented dur
  • Usual Care (Other)
    Usual care corresponds to usual practices regarding smoking cessation activities in participating sectors. Those practices may vary (enquiring whether a patient is a smoker or not, offering smoking cessation if they are or only if the patient asks, etc.)

Eligibility criteria

Inclusion Criteria: * Regular smokers (at least one cigarette per day) * Followed in psychiatric ambulatory care at one of the participating sectors' CMPs * Adults (18 years or older) * Covered by the statuary health insurance * Who gave their informed consent to participate to the study Exclusion Criteria: * Users under guardianship or legal protection, * Psychological state incompatible with completing the questionnaire, * Persons with no command or understanding of the French language

Conditions

Tobacco Addiction

Locations

  • Public mental health establishment of Lille Metropole (59G16-G17) — Armentières, France
  • Public mental health establishment of Lille Metropole (59G21) — Armentières, France
  • Flanders public mental health establishment (59G05/06) — Bailleul, France
  • Barthelemy Durand public health establishment (91G05) — Étampes, France
  • Psychotherapeutic center of Nancy (54G02-06) — Laxou, France
  • University Hospital Center of Lille (59G08) — Lille, France
  • Hospital Care Center of Nanterre (92G10) — Nanterre, France
  • University Hospital Group Paris Neurosciences & Psychiatry (75G04) — Paris, France
  • Hospital Center of Rouffach (68G02/03) — Rouffach, France
  • Hospital Center of Rouffach (68G08/09) — Rouffach, France
  • Hospital Center of Rouffach (Pôle LTD - 68G04/05) — Rouffach, France
  • Hospitals of Paris Est Val de Marne (94G01) — Saint-Maurice, France
  • Hospitals of Paris Est Val de Marne (94G16) — Saint-Maurice, France
  • Hospitals of Paris Est Val de Marne (Paris 11) — Saint-Maurice, France
  • Hospitals of Paris Est Val de Marne (Paris 12) — Saint-Maurice, France
  • Hospitals of Paris Est Val de Marne (Paris Centre) — Saint-Maurice, France
  • Public mental health establishment of Val de Lys Artois (62G09) — Saint-Venant, France
  • Public mental health establishment of Val de Lys Artois (62G12) — Saint-Venant, France
  • Public mental health establishment of Val de Lys Artois (Pôle du Ternois) — Saint-Venant, France
  • Public mental health establishment of Guadeloupe (96G01) — Saint-Claude, Guadeloupe
  • Public mental health establishment of Guadeloupe (96G06) — Saint-Claude, Guadeloupe
  • Public mental health establishment of Reunion Island (Pôle Nord) — Saint-Paul, Reunion
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record